e- Case Report
Response to Omalizumab in Solar Urticaria: Report of 3 Cases
Respuesta a omalizumab en 3 casos de urticaria solar
P. Rodríguez-Jiménez
, P. Chicharro, A. Pérez-Plaza, D. de Argila
Autor para correspondencia
Servicio de Dermatología, Hospital Universitario de La Princesa, Madrid, Spain
Leído
5311
Vecesse ha leído el artículo
1908
Total PDF
3403
Total HTML
Compartir estadísticas
array:24 [ "pii" => "S1578219017302408" "issn" => "15782190" "doi" => "10.1016/j.adengl.2016.08.019" "estado" => "S300" "fechaPublicacion" => "2017-10-01" "aid" => "1655" "copyright" => "Elsevier España, S.L.U. and AEDV" "copyrightAnyo" => "2017" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "crp" "cita" => "Actas Dermosifiliogr. 2017;108:e53-5" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 521 "formatos" => array:3 [ "EPUB" => 35 "HTML" => 366 "PDF" => 120 ] ] "Traduccion" => array:1 [ "es" => array:19 [ "pii" => "S0001731017301734" "issn" => "00017310" "doi" => "10.1016/j.ad.2016.08.011" "estado" => "S300" "fechaPublicacion" => "2017-10-01" "aid" => "1655" "copyright" => "AEDV" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "crp" "cita" => "Actas Dermosifiliogr. 2017;108:e53-5" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 201 "formatos" => array:3 [ "EPUB" => 2 "HTML" => 133 "PDF" => 66 ] ] "es" => array:12 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">e-Casos clínicos</span>" "titulo" => "Respuesta a omalizumab en 3 casos de urticaria solar" "tienePdf" => "es" "tieneTextoCompleto" => "es" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "e53" "paginaFinal" => "e55" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Response to Omalizumab in Solar Urticaria: Report of 3 Cases" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "P. Rodríguez-Jiménez, P. Chicharro, A. Pérez-Plaza, D. de Argila" "autores" => array:4 [ 0 => array:2 [ "nombre" => "P." "apellidos" => "Rodríguez-Jiménez" ] 1 => array:2 [ "nombre" => "P." "apellidos" => "Chicharro" ] 2 => array:2 [ "nombre" => "A." "apellidos" => "Pérez-Plaza" ] 3 => array:2 [ "nombre" => "D." "apellidos" => "de Argila" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S1578219017302408" "doi" => "10.1016/j.adengl.2016.08.019" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219017302408?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731017301734?idApp=UINPBA000044" "url" => "/00017310/0000010800000008/v1_201710010019/S0001731017301734/v1_201710010019/es/main.assets" ] ] "itemSiguiente" => array:19 [ "pii" => "S157821901730241X" "issn" => "15782190" "doi" => "10.1016/j.adengl.2017.07.004" "estado" => "S300" "fechaPublicacion" => "2017-10-01" "aid" => "1505" "copyright" => "Elsevier España, S.L.U. and AEDV" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "crp" "cita" => "Actas Dermosifiliogr. 2017;108:771-2" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 455 "formatos" => array:3 [ "EPUB" => 30 "HTML" => 340 "PDF" => 85 ] ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Case and Research Letter</span>" "titulo" => "Exophytic Tumor on the Left Temple" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "771" "paginaFinal" => "772" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Tumoración excrecente en sien izquierda" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:6 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 875 "Ancho" => 1167 "Tamanyo" => 242427 ] ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "E. Varas-Meis, M.M. Otero-Rivas, M.Á. Rodriguez-Prieto" "autores" => array:3 [ 0 => array:2 [ "nombre" => "E." "apellidos" => "Varas-Meis" ] 1 => array:2 [ "nombre" => "M.M." "apellidos" => "Otero-Rivas" ] 2 => array:2 [ "nombre" => "M.Á." "apellidos" => "Rodriguez-Prieto" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S000173101630312X" "doi" => "10.1016/j.ad.2016.02.026" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S000173101630312X?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S157821901730241X?idApp=UINPBA000044" "url" => "/15782190/0000010800000008/v1_201710010015/S157821901730241X/v1_201710010015/en/main.assets" ] "itemAnterior" => array:18 [ "pii" => "S1578219017302391" "issn" => "15782190" "doi" => "10.1016/j.adengl.2017.07.003" "estado" => "S300" "fechaPublicacion" => "2017-10-01" "aid" => "1673" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Actas Dermosifiliogr. 2017;108:758-70" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 693 "formatos" => array:3 [ "EPUB" => 28 "HTML" => 479 "PDF" => 186 ] ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original</span>" "titulo" => "Preservatives in Personal Hygiene and Cosmetic Products, Topical Medications, and Household Cleaners in Spain" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "758" "paginaFinal" => "770" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Conservantes en productos de higiene y cosméticos, medicamentos tópicos y productos de limpieza doméstica en España" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0025" "etiqueta" => "Figure 5" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr5.jpeg" "Alto" => 1384 "Ancho" => 3325 "Tamanyo" => 223849 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0075" class="elsevierStyleSimplePara elsevierViewall">Percentage of brands containing the main preservatives used in the dermocosmetics sector. IPBC, iodopropynyl butylcarbamate; MCI, methylchloroisothiazolinone; MI, methylisothiazolinone; PAPB, polyaminopropyl biguanide.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "María Antonia Pastor-Nieto, Francisco Alcántara-Nicolás, Virginia Melgar-Molero, Raquel Pérez-Mesonero, Aránzazu Vergara-Sánchez, Adriana Martín-Fuentes, Patricia González-Muñoz, Esther de Eusebio-Murillo" "autores" => array:8 [ 0 => array:2 [ "nombre" => "María Antonia" "apellidos" => "Pastor-Nieto" ] 1 => array:2 [ "nombre" => "Francisco" "apellidos" => "Alcántara-Nicolás" ] 2 => array:2 [ "nombre" => "Virginia" "apellidos" => "Melgar-Molero" ] 3 => array:2 [ "nombre" => "Raquel" "apellidos" => "Pérez-Mesonero" ] 4 => array:2 [ "nombre" => "Aránzazu" "apellidos" => "Vergara-Sánchez" ] 5 => array:2 [ "nombre" => "Adriana" "apellidos" => "Martín-Fuentes" ] 6 => array:2 [ "nombre" => "Patricia" "apellidos" => "González-Muñoz" ] 7 => array:2 [ "nombre" => "Esther" "apellidos" => "de Eusebio-Murillo" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0001731017302053" "doi" => "10.1016/j.ad.2017.04.003" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731017302053?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219017302391?idApp=UINPBA000044" "url" => "/15782190/0000010800000008/v1_201710010015/S1578219017302391/v1_201710010015/en/main.assets" ] "en" => array:17 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">e- Case Report</span>" "titulo" => "Response to Omalizumab in Solar Urticaria: Report of 3 Cases" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "e53" "paginaFinal" => "e55" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "P. Rodríguez-Jiménez, P. Chicharro, A. Pérez-Plaza, D. de Argila" "autores" => array:4 [ 0 => array:4 [ "nombre" => "P." "apellidos" => "Rodríguez-Jiménez" "email" => array:1 [ 0 => "pedro.rodriguez.jimenez90@gmail.com" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] 1 => array:2 [ "nombre" => "P." "apellidos" => "Chicharro" ] 2 => array:2 [ "nombre" => "A." "apellidos" => "Pérez-Plaza" ] 3 => array:2 [ "nombre" => "D." "apellidos" => "de Argila" ] ] "afiliaciones" => array:1 [ 0 => array:2 [ "entidad" => "Servicio de Dermatología, Hospital Universitario de La Princesa, Madrid, Spain" "identificador" => "aff0005" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Respuesta a omalizumab en 3 casos de urticaria solar" ] ] "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall">Solar urticaria (SU) is an uncommon chronic inducible urticaria characterized by the development of wheals after exposure to sun radiation, visible light, or UV radiation. Because the condition is rare, there are no epidemiological data on incidence or prevalence rates,<a class="elsevierStyleCrossRef" href="#bib0080"><span class="elsevierStyleSup">1</span></a> although varying figures of between 2.3% and 17.8% have been reported within the group of photodermatoses.<a class="elsevierStyleCrossRef" href="#bib0080"><span class="elsevierStyleSup">1</span></a> Lesions typically appear within minutes of exposure and the most common action spectra are visible light and UV-A. Action spectrum and minimal urticaria dose (MUD) are important for diagnosis, treatment, and prognosis, and can be used to rule out other photodermatoses.<a class="elsevierStyleCrossRef" href="#bib0085"><span class="elsevierStyleSup">2</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">Second-generation H<span class="elsevierStyleInf">1</span> antihistamines are the first-line treatment for inducible chronic SU, just as they are for other forms of inducible chronic urticaria. However, most patients require either high doses or combinations of different antihistamines.<a class="elsevierStyleCrossRef" href="#bib0085"><span class="elsevierStyleSup">2</span></a> An alternative first-line approach is tolerance induction through phototherapy.<a class="elsevierStyleCrossRef" href="#bib0085"><span class="elsevierStyleSup">2</span></a> The use of omalizumab has also been described in several case reports and small case series of patients in recent years, with varying results. The principle underlying this treatment is based on a hypothetic role for immunoglobulin (Ig) E in the pathogenesis of inducible chronic urticaria.<a class="elsevierStyleCrossRef" href="#bib0090"><span class="elsevierStyleSup">3</span></a></p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0030">Case Descriptions</span><p id="par0015" class="elsevierStylePara elsevierViewall">The clinical data for 3 patients with severe SU refractory to H<span class="elsevierStyleInf">1</span> antihistamines treated in our department over a period of 5 years are summarized in <a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>.</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0020" class="elsevierStylePara elsevierViewall">Patient 1 had SU induced by visible light in which neither H<span class="elsevierStyleInf">1</span> antihistamines nor phototherapy proved effective. Following treatment with omalizumab, however, she exhibited clear signs of clinical improvement (she was able to tolerate sunlight for 10 times longer than before) and improved test results after photoprovocation testing. Patient 2 had SU to visible light triggered by indoor lights (fluorescents and LEDs) that prevented her from spending time in the sun. After treatment with omalizumab, she experienced an increase in tolerance of exposure to both indoor lights and sunlight. She is now able to remain in the sun for up to 5<span class="elsevierStyleHsp" style=""></span>hours, something that she had not been able to do for 15 years. She also showed improved objective health-related quality of life scores on the Skindex-29 compared with baseline, with a 23% improvement noted for overall quality of life, and additional improvements in the Symptoms, Emotions, and Functioning domains. Patient 3, whose case has been previously published,<a class="elsevierStyleCrossRef" href="#bib0095"><span class="elsevierStyleSup">4</span></a> had SU due to UV-B and UV-A and a very low MUD that limited the use of phototherapy. She had responded poorly to H<span class="elsevierStyleInf">1</span> antihistamines. She was treated twice with omalizumab but showed no response on either occasion. In addition, she developed a mild local reaction after the first injection in the form of pruritic wheals that resolved spontaneously.</p></span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">Discussion</span><p id="par0025" class="elsevierStylePara elsevierViewall">In our review of the literature, we identified 16 patients with SU treated with omalizumab (8 case reports and 3 case series).<a class="elsevierStyleCrossRefs" href="#bib0090"><span class="elsevierStyleSup">3–14</span></a> Fourteen of the patients were adults and 2 were children.<a class="elsevierStyleCrossRefs" href="#bib0100"><span class="elsevierStyleSup">5,6</span></a> The treatment doses varied between 150<span class="elsevierStyleHsp" style=""></span>mg/mo<span class="elsevierStyleSup">7</span> and 800<span class="elsevierStyleHsp" style=""></span>mg/mo.<a class="elsevierStyleCrossRef" href="#bib0115"><span class="elsevierStyleSup">8</span></a> Varying measures of clinical response were used, and not all authors reported on this aspect of treatment. Most authors used subjective criteria based on patient-reported manifestations or other health-related quality of life measures. Others used phototesting<a class="elsevierStyleCrossRefs" href="#bib0105"><span class="elsevierStyleSup">6–9</span></a> or the Urticaria Activity Score 7, which is a validated tool for evaluating chronic urticaria.<a class="elsevierStyleCrossRef" href="#bib0125"><span class="elsevierStyleSup">10</span></a> Of the 16 patients, 12 (75%) responded either partially or completely to treatment and 5 of these (31.2%) additionally showed negative provocation results. Follow-up time varied from 1 month, in a patient who showed complete response after a single dose,<a class="elsevierStyleCrossRef" href="#bib0110"><span class="elsevierStyleSup">7</span></a> to 1 year, in a patient who received 12 monthly doses.<a class="elsevierStyleCrossRef" href="#bib0105"><span class="elsevierStyleSup">6</span></a></p><p id="par0030" class="elsevierStylePara elsevierViewall">On analyzing the cases reviewed, we observed a certain tendency towards an association between high total baseline IgE levels, albeit variable, and greater response to treatment. Seven of the 8 patients in this subgroup responded to treatment, although it should be noted that some of the responders had normal IgE levels, while some of the nonresponders (like patient #3 in our series) had elevated levels.</p><p id="par0035" class="elsevierStylePara elsevierViewall">No severe adverse effects were mentioned in the cases reviewed, and it is noteworthy that the treatment proved safe in the 2 pediatric cases described.<a class="elsevierStyleCrossRefs" href="#bib0100"><span class="elsevierStyleSup">5,6</span></a></p><p id="par0040" class="elsevierStylePara elsevierViewall">Finally, Aubin et al.<a class="elsevierStyleCrossRef" href="#bib0150"><span class="elsevierStyleSup">15</span></a> recently reported on results from a phase II clinical trial investigating the use of omalizumab (300<span class="elsevierStyleHsp" style=""></span>mg/mo for 2 months) in 10 patients with SU studied by phototesting and photoprovocation (action spectra: UV-A, UV-B, and polychromatic solar spectrum). The primary endpoint was the proportion of patients who did not develop SU lesions after photoprovocation with a UV radiation dose 10 times higher than the baseline MUD after 12 weeks of treatment. Approximately 40% of the patients showed an initial clinical improvement, but the efficacy results based on the primary endpoint showed no significant differences.</p><p id="par0045" class="elsevierStylePara elsevierViewall">In conclusion, despite the limited data available from case reports and small case series on the characteristics and results of SU treatment with omalizumab, the clinical response rate of 75% based on reports in the literature to date is promising. The 3 patients described in our series are a selection of patients with severe SU treated at our department and omalizumab proved effective in 2 of them. Response was slower than that typically described for spontaneous chronic urticaria, with improvement observed after 3 doses (patient #1) or 5 doses (patient #2). Both patients are satisfied with the results and wish to continue treatment. Omalizumab may therefore be a potentially safe and useful treatment for patients with severe SU that is refractory to conventional treatment.</p></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">Ethical Disclosures</span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Protection of humans and animals</span><p id="par0050" class="elsevierStylePara elsevierViewall">The authors declare that no tests were carried out in humans or animals for the purpose of this study.</p></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">Confidentiality of data</span><p id="par0055" class="elsevierStylePara elsevierViewall">The authors declare that they have followed their hospital's protocol on the publication of data concerning patients.</p></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0055">Right to privacy and informed consent</span><p id="par0060" class="elsevierStylePara elsevierViewall">The authors declare that no private patient data appear in this article.</p></span></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0060">Conflicts of Interest</span><p id="par0065" class="elsevierStylePara elsevierViewall">Dr de Argila has worked as a clinical advisor for Novartis and also participated in clinical trials sponsored by this company. The other authors declare no conflicts of interest.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:10 [ 0 => array:3 [ "identificador" => "xres908305" "titulo" => "Abstract" "secciones" => array:1 [ 0 => array:1 [ "identificador" => "abst0005" ] ] ] 1 => array:2 [ "identificador" => "xpalclavsec888229" "titulo" => "Keywords" ] 2 => array:3 [ "identificador" => "xres908304" "titulo" => "Resumen" "secciones" => array:1 [ 0 => array:1 [ "identificador" => "abst0010" ] ] ] 3 => array:2 [ "identificador" => "xpalclavsec888228" "titulo" => "Palabras clave" ] 4 => array:2 [ "identificador" => "sec0005" "titulo" => "Introduction" ] 5 => array:2 [ "identificador" => "sec0010" "titulo" => "Case Descriptions" ] 6 => array:2 [ "identificador" => "sec0015" "titulo" => "Discussion" ] 7 => array:3 [ "identificador" => "sec0020" "titulo" => "Ethical Disclosures" "secciones" => array:3 [ 0 => array:2 [ "identificador" => "sec0025" "titulo" => "Protection of humans and animals" ] 1 => array:2 [ "identificador" => "sec0030" "titulo" => "Confidentiality of data" ] 2 => array:2 [ "identificador" => "sec0035" "titulo" => "Right to privacy and informed consent" ] ] ] 8 => array:2 [ "identificador" => "sec0040" "titulo" => "Conflicts of Interest" ] 9 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "PalabrasClave" => array:2 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec888229" "palabras" => array:3 [ 0 => "Inducible chronic urticaria" 1 => "Omalizumab" 2 => "Solar urticaria" ] ] ] "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec888228" "palabras" => array:3 [ 0 => "Urticaria crónica inducible" 1 => "Omalizumab" 2 => "Urticaria solar" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:2 [ "titulo" => "Abstract" "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">We report 3 cases of solar urticaria in which there was no response or limited response to first-line treatments with high-dose H<span class="elsevierStyleInf">1</span> antihistamines or phototherapy. The patients were then treated with omalizumab. Symptoms improved in 2 patients, whose tolerance to sunlight increased considerably; quality of life clearly improved for 1 of these patients. The third experienced no improvement and developed a mild local reaction to the injected medication. We conclude that omalizumab may offer a potentially safe, useful alternative for patients with solar urticaria who do not respond to conventional therapy.</p></span>" ] "es" => array:2 [ "titulo" => "Resumen" "resumen" => "<span id="abst0010" class="elsevierStyleSection elsevierViewall"><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Se presentan 3 pacientes con urticaria solar que o no habían respondido adecuadamente o presentaban limitaciones a los tratamientos de primera línea (antihistamínicos H1 a dosis altas o fototerapia), que fueron tratados con omalizumab. Dos de ellos mejoraron clínicamente con un aumento muy importante de la tolerancia a la luz, uno de ellos con clara mejoría de la calidad de vida. El otro paciente no mejoró y desarrolló una reacción local leve a la medicación inyectada. Omalizumab puede ser por tanto una alternativa terapéutica potencialmente útil y segura en urticarias solares graves no respondedoras al tratamiento convencional.</p></span>" ] ] "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Please cite this article as: Rodríguez-Jiménez P, Chicharro P, Pérez-Plaza A, de Argila D. Respuesta a omalizumab en 3 casos de urticaria solar. Actas Dermosifiliogr. 2017;108:e53–e55.</p>" ] ] "multimedia" => array:1 [ 0 => array:8 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at1" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "leyenda" => "<p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">Abbreviations: ARC, allergic rhinoconjunctivitis; Com, comorbid conditions; FL, fluorescent light; H<span class="elsevierStyleInf">1</span>A, H<span class="elsevierStyleInf">1</span> antihistamines; IgE, immunoglobulin E; MUD, minimal urticaria dose; PLE, polymorphic light eruption; PT, previous treatment; TsO, time since onset; Unr, unremarkable; VL, visible light.</p>" "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Sex \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Age, y \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Com \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">TsO, y \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">PT \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">MUD \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">IgE \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Dose During Treatment \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Clinical Response \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">F \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">53 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">ARC \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">H<span class="elsevierStyleInf">1</span>A PT \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Wheal after 30<span class="elsevierStyleHsp" style=""></span>min with VL \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">502<span class="elsevierStyleHsp" style=""></span>IU/mL \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">300<span class="elsevierStyleHsp" style=""></span>mg/mo 12 mo \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Complete with negative provocation test results \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">F \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">65 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">PLE \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">10 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">H<span class="elsevierStyleInf">1</span>A \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Wheal after 30<span class="elsevierStyleHsp" style=""></span>min with FL \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">17.2<span class="elsevierStyleHsp" style=""></span>IU/mL \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">300<span class="elsevierStyleHsp" style=""></span>mg/mo 6 mo \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Partial \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">F \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">50 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Unr \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">25 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">H<span class="elsevierStyleInf">1</span>A \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">UV-B, 10<span class="elsevierStyleHsp" style=""></span>mj/cm<span class="elsevierStyleSup">2</span>; UV-A, <<span class="elsevierStyleHsp" style=""></span>0.6<span class="elsevierStyleHsp" style=""></span>mj/cm<span class="elsevierStyleSup">2</span>; SS, <<span class="elsevierStyleHsp" style=""></span>10<span class="elsevierStyleHsp" style=""></span>mj/cm<span class="elsevierStyleSup">2</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1382<span class="elsevierStyleHsp" style=""></span>IU/mL \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">150<span class="elsevierStyleHsp" style=""></span>mg/2<span class="elsevierStyleHsp" style=""></span>wk 1.5 mo \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">No clinical or objective response \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">300<span class="elsevierStyleHsp" style=""></span>mg/mo 4 mo \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1527680.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Cases of Solar Urticaria Treated With Omalizumab.</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0015" "bibliografiaReferencia" => array:15 [ 0 => array:3 [ "identificador" => "bib0080" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Solar urticaria" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "N. Botto" 1 => "E. Warshaw" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaad.2008.08.020" "Revista" => array:7 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "2008" "volumen" => "59" "paginaInicial" => "909" "paginaFinal" => "920" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19022098" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0140673610606745" "estado" => "S300" "issn" => "01406736" ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0085" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The definition, diagnostic testing, and management of chronic inducible urticarias - The EAACI/GA2LEN/EDF/UNEV consensus recommendations 2016 update and revision" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Magerl" 1 => "S. Altrichter" 2 => "E. Borzova" 3 => "A. Giménez-Arnau" 4 => "C. Grattan" 5 => "F. Lawlor" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/all.12884" "Revista" => array:7 [ "tituloSerie" => "Allergy" "fecha" => "2016" "volumen" => "71" "paginaInicial" => "780" "paginaFinal" => "802" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26991006" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0140673610620399" "estado" => "S300" "issn" => "01406736" ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0090" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Anti-immunoglobulin E treatment of patients with recalcitrant physical urticaria" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Metz" 1 => "S. Altrichter" 2 => "E. Ardelean" 3 => "B. Kessler" 4 => "K. Krause" 5 => "M. Magerl" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1159/000320233" "Revista" => array:6 [ "tituloSerie" => "Int Arch Allergy Immunol" "fecha" => "2011" "volumen" => "154" "paginaInicial" => "177" "paginaFinal" => "180" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20733327" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0095" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Failure of omalizumab in ultraviolet-induced severe solar urticaria" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "A. Pérez-Plaza" 1 => "M.J. Concha-Garzón" 2 => "G. Solano-López" 3 => "D. De Argila" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Immunology" "fecha" => "2014" "volumen" => "33" "paginaInicial" => "147" "paginaFinal" => "148" ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0100" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Treatment with omalizumab in a 16- year-old Caucasian girl with refractory solar urticaria" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S. Arasi" 1 => "G. Crisafulli" 2 => "L. Caminiti" 3 => "F. Guarneri" 4 => "T. Aversa" 5 => "F. Porcaro" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/pai.12413" "Revista" => array:7 [ "tituloSerie" => "Pediatr Allergy Immunol" "fecha" => "2015" "volumen" => "26" "paginaInicial" => "583" "paginaFinal" => "585" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26033828" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0870255115000086" "estado" => "S300" "issn" => "08702551" ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0105" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Successful omalizumab treatment of severe solar urticaria in a 6-year-old child" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "A. Levi" 1 => "Y. Tal" 2 => "Z. Dranitzki" 3 => "M. Shalit" 4 => "D.E. Claes" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/pai.12441" "Revista" => array:6 [ "tituloSerie" => "Pediatr Allergy Immunol" "fecha" => "2015" "volumen" => "26" "paginaInicial" => "588" "paginaFinal" => "590" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26172942" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0110" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Successful treatment of solar urticaria with anti-immunoglobulin E therapy" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "O. Güzelbey" 1 => "E. Ardelean" 2 => "M. Magerl" 3 => "T. Zuberbier" 4 => "M. Maurer" 5 => "M. Metz" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1398-9995.2008.01879.x" "Revista" => array:6 [ "tituloSerie" => "Allergy" "fecha" => "2008" "volumen" => "63" "paginaInicial" => "1563" "paginaFinal" => "1565" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18925897" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0115" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Partial improvement of solar urticaria after omalizumab" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "K.H. Waibel" 1 => "D.A. Reese" 2 => "R.G. Hamilton" 3 => "R. Devillez" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaci.2009.11.007" "Revista" => array:6 [ "tituloSerie" => "J Allergy Clin Immunol" "fecha" => "2010" "volumen" => "125" "paginaInicial" => "490" "paginaFinal" => "491" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20159260" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0120" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effectiveness of omalizumab in severe solar urticaria" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "A. De Dios-Velázquez" 1 => "M. Gónzalez-De Arriba" 2 => "V. Beteta-Gorriti" 3 => "E. Macías" 4 => "V. Campanón-Toro" 5 => "I. Dávila" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.anai.2015.11.019" "Revista" => array:6 [ "tituloSerie" => "Ann Allergy Asthma Immunol" "fecha" => "2016" "volumen" => "116" "paginaInicial" => "256" "paginaFinal" => "264" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26774975" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0125" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Three cases of solar urticaria successfully treated with omalizumab" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "C. Baliu-Piqué" 1 => "P. Aguilera-Peiró" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/jdv.13001" "Revista" => array:6 [ "tituloSerie" => "J Eur Acad Dermatol Venereol" "fecha" => "2015" "volumen" => "30" "paginaInicial" => "704" "paginaFinal" => "706" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25640906" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0130" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: A retrospective clinical analysis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "M. Metz" 1 => "T. Ohanyan" 2 => "M.K. Church" 3 => "M. Maurer" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jdermsci.2013.08.011" "Revista" => array:7 [ "tituloSerie" => "J Dermatol Sci" "fecha" => "2014" "volumen" => "73" "paginaInicial" => "57" "paginaFinal" => "62" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24060603" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0735109713062335" "estado" => "S300" "issn" => "07351097" ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0135" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Unique co-existence of cold and solar urticaria and its efficient treatment" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "S. Zimmer" 1 => "A. Pevelling-Oberhag" 2 => "A. Weber" 3 => "T.T. Gilfert" 4 => "U. Rady-Pizarro" 5 => "P. Staubach" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/bjd.14354" "Revista" => array:7 [ "tituloSerie" => "Br J Dermatol" "fecha" => "2016" "volumen" => "174" "paginaInicial" => "1150" "paginaFinal" => "1152" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26678859" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0140673609605663" "estado" => "S300" "issn" => "01406736" ] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0140" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Failure of omalizumab (Xolair) in the treatment of a case of solar urticaria caused by ultraviolet A and visible light" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "G. Duchini" 1 => "W. Bäumler" 2 => "A.J. Bircher" 3 => "K. Scherer" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1600-0781.2011.00624.x" "Revista" => array:6 [ "tituloSerie" => "Photodermatol Photoimmunol Photomed" "fecha" => "2011" "volumen" => "27" "paginaInicial" => "336" "paginaFinal" => "337" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22092741" "web" => "Medline" ] ] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0145" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Failure of omalizumab in the treatment of solar urticaria" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "S. Müller" 1 => "C.M. Schempp" 2 => "T. Jakob" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/jdv.12922" "Revista" => array:6 [ "tituloSerie" => "J Eur Acad Dermatol Venereol" "fecha" => "2016" "volumen" => "30" "paginaInicial" => "524" "paginaFinal" => "525" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25546321" "web" => "Medline" ] ] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0150" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Omalizumab in patients with severe and refractory solar urticaria: A phase II multicentric study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "F. Aubin" 1 => "M. Avenel-Audran" 2 => "M. Jeanmougin" 3 => "H. Adamski" 4 => "J.L. Peyron" 5 => "M.C. Marguery" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaad.2015.11.021" "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "2016" "volumen" => "74" "paginaInicial" => "574" "paginaFinal" => "575" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26892659" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/15782190/0000010800000008/v1_201710010015/S1578219017302408/v1_201710010015/en/main.assets" "Apartado" => array:4 [ "identificador" => "34944" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "e- Case Report" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/15782190/0000010800000008/v1_201710010015/S1578219017302408/v1_201710010015/en/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219017302408?idApp=UINPBA000044" ]
| año/Mes | Html | Total | |
|---|---|---|---|
| 2024 Noviembre | 12 | 6 | 18 |
| 2024 Octubre | 86 | 49 | 135 |
| 2024 Septiembre | 85 | 27 | 112 |
| 2024 Agosto | 116 | 50 | 166 |
| 2024 Julio | 101 | 29 | 130 |
| 2024 Junio | 118 | 37 | 155 |
| 2024 Mayo | 65 | 31 | 96 |
| 2024 Abril | 82 | 31 | 113 |
| 2024 Marzo | 77 | 25 | 102 |
| 2024 Febrero | 47 | 26 | 73 |
| 2024 Enero | 55 | 41 | 96 |
| 2023 Diciembre | 49 | 22 | 71 |
| 2023 Noviembre | 77 | 29 | 106 |
| 2023 Octubre | 61 | 26 | 87 |
| 2023 Septiembre | 75 | 30 | 105 |
| 2023 Agosto | 28 | 21 | 49 |
| 2023 Julio | 67 | 39 | 106 |
| 2023 Junio | 39 | 21 | 60 |
| 2023 Mayo | 51 | 25 | 76 |
| 2023 Abril | 64 | 14 | 78 |
| 2023 Marzo | 47 | 17 | 64 |
| 2023 Febrero | 56 | 21 | 77 |
| 2023 Enero | 44 | 24 | 68 |
| 2022 Diciembre | 61 | 44 | 105 |
| 2022 Noviembre | 31 | 25 | 56 |
| 2022 Octubre | 19 | 14 | 33 |
| 2022 Septiembre | 27 | 45 | 72 |
| 2022 Agosto | 33 | 38 | 71 |
| 2022 Julio | 25 | 45 | 70 |
| 2022 Junio | 27 | 20 | 47 |
| 2022 Mayo | 42 | 42 | 84 |
| 2022 Abril | 63 | 35 | 98 |
| 2022 Marzo | 61 | 63 | 124 |
| 2022 Febrero | 37 | 51 | 88 |
| 2022 Enero | 50 | 34 | 84 |
| 2021 Diciembre | 33 | 36 | 69 |
| 2021 Noviembre | 37 | 51 | 88 |
| 2021 Octubre | 54 | 59 | 113 |
| 2021 Septiembre | 31 | 38 | 69 |
| 2021 Agosto | 57 | 52 | 109 |
| 2021 Julio | 41 | 32 | 73 |
| 2021 Junio | 54 | 30 | 84 |
| 2021 Mayo | 49 | 45 | 94 |
| 2021 Abril | 95 | 56 | 151 |
| 2021 Marzo | 75 | 33 | 108 |
| 2021 Febrero | 69 | 30 | 99 |
| 2021 Enero | 48 | 27 | 75 |
| 2020 Diciembre | 64 | 25 | 89 |
| 2020 Noviembre | 34 | 17 | 51 |
| 2020 Octubre | 51 | 11 | 62 |
| 2020 Septiembre | 50 | 20 | 70 |
| 2020 Agosto | 39 | 28 | 67 |
| 2020 Julio | 38 | 18 | 56 |
| 2020 Junio | 49 | 35 | 84 |
| 2020 Mayo | 25 | 21 | 46 |
| 2020 Abril | 31 | 14 | 45 |
| 2020 Marzo | 32 | 13 | 45 |
| 2020 Febrero | 7 | 0 | 7 |
| 2020 Enero | 4 | 0 | 4 |
| 2019 Diciembre | 8 | 0 | 8 |
| 2019 Noviembre | 2 | 0 | 2 |
| 2019 Septiembre | 8 | 0 | 8 |
| 2019 Agosto | 6 | 0 | 6 |
| 2019 Julio | 4 | 0 | 4 |
| 2019 Junio | 7 | 0 | 7 |
| 2019 Mayo | 3 | 1 | 4 |
| 2019 Abril | 4 | 0 | 4 |
| 2019 Marzo | 4 | 0 | 4 |
| 2019 Febrero | 2 | 0 | 2 |
| 2019 Enero | 5 | 0 | 5 |
| 2018 Diciembre | 3 | 0 | 3 |
| 2018 Noviembre | 2 | 0 | 2 |
| 2018 Octubre | 3 | 0 | 3 |
| 2018 Septiembre | 3 | 0 | 3 |
| 2018 Agosto | 1 | 0 | 1 |
| 2018 Febrero | 24 | 5 | 29 |
| 2018 Enero | 38 | 7 | 45 |
| 2017 Diciembre | 50 | 14 | 64 |
| 2017 Noviembre | 46 | 11 | 57 |
| 2017 Octubre | 131 | 54 | 185 |
| 2017 Septiembre | 1 | 17 | 18 |
| 2017 Agosto | 3 | 11 | 14 |
Mostrar todo
